CFA
ALXN

Camarda Financial Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Camarda Financial Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-37
Closed -$5K – 502
2019
Q2 		$5K Buy
+37
New +$4.77K 0.01% 210
2017
Q1 		– Sell
-19
Closed -$2K – 265
2016
Q4 		$2K Buy
+19
New +$2.33K ﹤0.01% 231
2016
Q1 		– Sell
-1,184
Closed -$226K – 316
2015
Q4 		$226K Buy
+1,184
New +$207K 0.14% 90
2015
Q2 		– Sell
-232
Closed -$40K – 282
2015
Q1 		$40K Buy
232
+71
+44% +$12.9K 0.02% 147
2014
Q4 		$30K Buy
+161
New +$29.8K 0.02% 165

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Camarda Financial Advisors's ALXN Position: Q3 2019 in Review

Camarda Financial Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2019, closing a stake of 37 shares — an estimated $5K sold.

Camarda Financial Advisors first reported a position in ALXN in Q4 2014 and held it in 5 quarters. The position peaked at $226K in Q4 2015. 648 funds tracked by Wall St. Rank hold ALXN as of Q3 2019.

  • Camarda Financial Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Camarda Financial Advisors sold 37 Alexion Pharmaceuticals shares in Q3 2019, an estimated $5K.
  • Camarda Financial Advisors first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 5 quarters.
  • Camarda Financial Advisors's Alexion Pharmaceuticals position peaked at $226K in Q4 2015.
  • 648 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2019.

Based on Camarda Financial Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.